BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. (BBNX) alleging that the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events.

The lawsuit claims thousands of complaints were filed with the FDA, contrary to defendants' assertions that they were benign. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff.

A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements regarding the safety and regulatory compliance of its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose FDA observations about quality management system deficiencies and underreported serious customer complaints. Investors who purchased Beta Bionics securities between July 30, 2025 and February 24, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 3, 2026.

A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements regarding FDA observations about its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose serious safety deficiencies and customer complaints, understating regulatory risks and safety concerns during the period from July 30, 2025 to February 24, 2026.

Rosen Law Firm is encouraging investors who purchased securities of Lincoln Educational Services (LINC), AST SpaceMobile (ASTS), and Beta Bionics (BBNX) during specified class periods to join securities class action lawsuits. The firm reminds investors of important lead plaintiff deadlines and notes that class actions have already been filed alleging false and misleading statements by defendants.

A securities class action lawsuit has been filed against Beta Bionics, Inc. for allegedly making false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events.

The lawsuit claims thousands of complaints were filed with the FDA, contrary to defendants' assertions that they were benign. The lead plaintiff deadline is November 3, 2026.

Rosen Law Firm is notifying Beta Bionics, Inc. investors of a November 3, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made false statements about its iLet Bionic Pancreas insulin pump, which the FDA found to be malfunctioning and causing dangerously high insulin dosing. The company allegedly failed to implement meaningful corrective actions despite thousands of complaints and hundreds of life-threatening events.

Robbins LLP reminds investors of a class action lawsuit against Beta Bionics (BBNX) for allegedly misleading investors about the safety and efficacy of its iLet insulin pump. The company failed to disclose serious FDA concerns about device malfunctions causing dangerously high insulin doses and hypoglycemic events. Stock fell from $31.99 to $12.89 per share between January and February 2026 following FDA warning letter disclosures.

Pomerantz Law Firm has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) alleging securities fraud related to its iLet insulin pump device. The company allegedly misrepresented FDA concerns and failed to properly report thousands of patient complaints.

The lawsuit follows significant stock price declines after the FDA issued a warning letter in February 2026, revealing more serious safety and reporting issues than Beta Bionics had previously disclosed. Investors have until November 3, 2026, to join the class action.

A securities class action lawsuit has been filed against Beta Bionics, Inc. (BBNX) for allegedly making false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and delivering dangerously high insulin doses, causing hypoglycemic events.

The company allegedly failed to implement meaningful corrective actions. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be eligible for compensation. The lead plaintiff deadline is November 3, 2026.

Rosen Law Firm is urging investors who purchased Beta Bionics common stock between July 30, 2025 and February 24, 2026 to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its iLet Bionic Pancreas insulin pump, which the FDA found was malfunctioning and dosing patients with dangerously high insulin levels.

The firm claims thousands of complaints were filed with the FDA, contradicting defendants' assertions that issues were benign. The lead plaintiff deadline is November 3, 2026.

Beta Bionics (NASDAQ: BBNX) faces a securities class action lawsuit for allegedly misleading investors about its iLet automated insulin delivery system. The company concealed thousands of safety complaints, including life-threatening hypoglycemic events, and failed to report them to the FDA as required. An FDA warning letter in February 2026 revealed the violations, causing significant shareholder losses during the class period of July 30, 2025 to February 24, 2026.

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Unicycive Therapeutics, Hims & Hers Health, and Beta Bionics. The lawsuits allege materially false statements and non-disclosure of material facts regarding regulatory risks, deceptive billing practices, data sharing, and device safety issues. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by November 2-3, 2026.

A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging securities fraud for failing to disclose material information about FDA safety violations and product issues. The company allegedly omitted over 18,000 complaints including life-threatening hypoglycemic events from FDA reports and misrepresented the severity of FDA observations. The lawsuit covers investors who purchased shares between July 30, 2025 and February 24, 2026, with a November 3, 2026 deadline to file as lead plaintiff.

A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly raised serious safety concerns including device malfunctions and dangerously high insulin dosing causing hypoglycemic events.

The lawsuit claims Beta Bionics failed to implement meaningful corrective actions despite thousands of complaints. Investors who purchased stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff.

A class action lawsuit has been filed against Beta Bionics (NASDAQ: BBNX) for investors who purchased stock between July 30, 2025 and February 24, 2026. The complaint alleges the company received thousands of complaints about serious device malfunctions in its iLet insulin pump caused by an overly aggressive dosing algorithm.

The FDA issued a warning letter on February 24, 2026 detailing violations and contradicting the company's prior statements about complaint severity, leading to a 37% stock decline. The lead plaintiff deadline is November 3, 2026.

The Rosen Law Firm is reminding investors who purchased Beta Bionics common stock between July 30, 2025 and February 24, 2026 of the November 3, 2026 deadline to file a securities class action lawsuit. The lawsuit alleges that Beta Bionics made false and misleading statements about its iLet Bionic Pancreas insulin pump system, which the FDA found to have serious malfunctions causing dangerous insulin levels and hypoglycemic events. The company allegedly failed to implement corrective measures despite FDA concerns.

Beta Bionics faces a securities class action lawsuit alleging the company failed to disclose that its iLet insulin pump had a malfunctioning automated dosing algorithm causing dangerously high insulin delivery and hypoglycemic events. The company allegedly received thousands of complaints it failed to report to the FDA, and an FDA Form 483 identified over 18,000 unreported complaints. Investors with losses exceeding $100,000 have until November 3, 2026 to file lead plaintiff applications.

Rosen Law Firm is soliciting investors in Beta Bionics, Inc. (NASDAQ: BBNX) who purchased stock between July 30, 2025 and February 24, 2026 to join a securities class action lawsuit. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its iLet Bionic Pancreas insulin pump, concealing that the FDA had raised serious safety concerns including device malfunctions causing dangerously high insulin dosing and thousands of complaints. The lead plaintiff deadline is November 3, 2026.

A class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements regarding FDA observations about its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose serious safety deficiencies, quality management issues, and unreported customer complaints involving serious injuries. Investors who purchased Beta Bionics securities between July 30, 2025 and February 24, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 3, 2026.

Beta Bionics announced a partnership with Senseonics to integrate the Eversense 365 continuous glucose monitor with its iLet and future mint AID systems. The integration, launching in Q4 2026, will make iLet compatible with more CGM manufacturers than any other AID system. Despite the strategic partnership, BBNX shares fell over 8% following the announcement.